Association between drug trough concentration and disease outcome before infliximab maintenance treatment in children with Crohn's disease.
10.7499/j.issn.1008-8830.2205181
- Author:
Xing DENG
1
;
Yi YU
1
;
Xin-Qiong WANG
1
;
Jia LI
1
;
Xu XU
1
;
Chun-Di XU
1
;
Yuan XIAO
1
Author Information
1. Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
- Publication Type:Journal Article
- Keywords:
Child;
Crohn's disease;
Infliximab;
Pediatric Crohn's disease activity index;
Simple Endoscopic Score for Crohn's disease;
Therapeutic drug monitoring
- MeSH:
Child;
Humans;
Infliximab/therapeutic use*;
Crohn Disease/drug therapy*;
Gastrointestinal Agents/therapeutic use*;
Retrospective Studies;
C-Reactive Protein/analysis*
- From:
Chinese Journal of Contemporary Pediatrics
2022;24(11):1246-1251
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To study the association between infliximab trough level (IFX-TL) prior to maintenance treatment and disease outcome in children with Crohn's disease (CD).
METHODS:A retrospective analysis was performed on 35 children with CD who received induction therapy with infliximab (IFX) and the measurement of IFX-TL before maintenance treatment from August 2018 to November 2021. Clinical data and laboratory markers at baseline and before maintenance treatment were collected, and the association between outcome and IFX-TL was analyzed.
RESULTS:The clinical remission group, endoscopic remission group, and combined remission group had a significantly higher IFX-TL level than the corresponding non-remission groups (P<0.05), and there was no significant difference in the IFX-TL level between the biological remission and non-biological remission groups (P>0.05). The receiver operating characteristic (ROC) curve showed that IFX-TL had an area under the ROC curve of 0.959 (95%CI: 0.894-1) in predicting clinical remission, with a sensitivity of 90% and a specificity of 100% at the optimal cutoff value of 2.3 µg/mL (P<0.001).
CONCLUSIONS:Among children with CD receiving infliximab induction therapy, the children achieving clinical and endoscopic remission before maintenance treatment tend to have a higher level of IFX-TL. IFX-TL has a certain predictive value for clinical remission.
